Genome Biology (Dec 2022)

METTL4-mediated nuclear N6-deoxyadenosine methylation promotes metastasis through activating multiple metastasis-inducing targets

  • Kai-Wen Hsu,
  • Joseph Chieh-Yu Lai,
  • Jeng-Shou Chang,
  • Pei-Hua Peng,
  • Ching-Hui Huang,
  • Der-Yen Lee,
  • Yu-Cheng Tsai,
  • Chi-Jung Chung,
  • Han Chang,
  • Chao-Hsiang Chang,
  • Ji-Lin Chen,
  • See-Tong Pang,
  • Ziyang Hao,
  • Xiao-Long Cui,
  • Chuan He,
  • Kou-Juey Wu

DOI
https://doi.org/10.1186/s13059-022-02819-3
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 37

Abstract

Read online

Abstract Background DNA N6-methyldeoxyadenosine (6mA) is rarely present in mammalian cells and its nuclear role remains elusive. Results Here we show that hypoxia induces nuclear 6mA modification through a DNA methyltransferase, METTL4, in hypoxia-induced epithelial-mesenchymal transition (EMT) and tumor metastasis. Co-expression of METTL4 and 6mA represents a prognosis marker for upper tract urothelial cancer patients. By RNA sequencing and 6mA chromatin immunoprecipitation-exonuclease digestion followed by sequencing, we identify lncRNA RP11-390F4.3 and one novel HIF-1α co-activator, ZMIZ1, that are co-regulated by hypoxia and METTL4. Other genes involved in hypoxia-mediated phenotypes are also regulated by 6mA modification. Quantitative chromatin isolation by RNA purification assay shows the occupancy of lncRNA RP11-390F4.3 on the promoters of multiple EMT regulators, indicating lncRNA-chromatin interaction. Knockdown of lncRNA RP11-390F4.3 abolishes METTL4-mediated tumor metastasis. We demonstrate that ZMIZ1 is an essential co-activator of HIF-1α. Conclusions We show that hypoxia results in enriched 6mA levels in mammalian tumor cells through METTL4. This METTL4-mediated nuclear 6mA deposition induces tumor metastasis through activating multiple metastasis-inducing genes. METTL4 is characterized as a potential therapeutic target in hypoxic tumors.

Keywords